文献速递前列腺癌

患者来源模型揭示去势抵抗性前列腺癌对核糖体靶向治疗敏感

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
PubMed 文献 · Eur Urol · 2018-07-23

本研究从两名患者的独立转移灶建立了四株患者来源异种移植瘤(PDX),涵盖雄激素受体(AR)轴异质性和AR阴性表型。利用离体PDX培养系统筛选药物,发现所有模型均对核糖体靶向药物CX-5461与CX-6258联合敏感。提示核糖体靶向治疗可能对多种去势抵抗性前列腺癌(CRPC)亚型有效。

要点

  • 新型PDX模型涵盖AR突变、结构重排和AR阴性神经内分泌样表型。
  • 所有异质性CRPC模型均对CX-5461联合CX-6258敏感。
  • 患者来源模型可用于优先筛选临床转化治疗策略。

核心结论

  • 核糖体靶向药物可能对包括AR阴性在内的多种CRPC亚型有效。

研究设计与样本

  • 从两名患者的独立转移灶建立四株PDX并进行整合基因组学表征。
  • 利用离体PDX培养系统测试合理选择的药物面板。

主要发现

  • 新PDX展示异质性耐药机制,包括已知和新型AR突变、AR基因组结构重排及神经内分泌样AR阴性表型。
  • 所有模型均对CX-5461与CX-6258联合敏感。

关键数值与推荐

  • 离体培养中通过Ki67和cleaved caspase-3免疫组化评估药物疗效。
  • 体内抗肿瘤疗效以肿瘤体积为主要终点,采用双尾t检验比较药物与对照。

临床怎么用

  • 核糖体靶向联合方案可能成为CRPC的候选治疗策略。
  • 患者来源模型可用于临床前优先筛选治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The intractability of castration-resistant prostate cancer (CRPC) is exacerbated by tumour heterogeneity, including diverse alterations to the androgen receptor (AR) axis and AR-independent phenotypes. The availability of additional models encompassing this heterogeneity would facilitate the identification of more effective therapies for CRPC. OBJECTIVE: To discover therapeutic strategies by exploiting patient-derived models that exemplify the heterogeneity of CRPC. DESIGN, SETTING, AND PARTICIPANTS: Four new patient-derived xenografts (PDXs) were established from independent metastases of two patients and characterised using integrative genomics. A panel of rationally selected drugs was tested using an innovative ex vivo PDX culture system. INTERVENTION: The following drugs were evaluated: AR signalling inhibitors (enzalutamide and galeterone), a PARP inhibitor (talazoparib), a chemotherapeutic (cisplatin), a CDK4/6 inhibitor (ribociclib), bromodomain and extraterminal (BET) protein inhibitors (iBET151 and JQ1), and inhibitors of ribosome biogenesis/function (RNA polymerase I inhibitor CX-5461 and pan-PIM kinase inhibitor CX-6258). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Drug efficacy in ex vivo cultures of PDX tissues was evaluated using immunohistochemistry for Ki67 and cleaved caspase-3 levels. Candidate drugs were also tested for antitumour efficacy in vivo, with tumour volume being the primary endpoint. Two-tailed t tests were used to compare drug and control treatments. RESULTS AND LIMITATIONS: Integrative genomics revealed that the new PDXs exhibited heterogeneous mechanisms of resistance, including known and novel AR mutations, genomic structural rearrangements of the AR gene, and a neuroendocrine-like AR-null phenotype. Despite their heterogeneity, all models were sensitive to the combination of ribosome-targeting agents CX-5461 and CX-6258. CONCLUSIONS: This study demonstrates that ribosome-targeting drugs may be effective against diverse CRPC subtypes including AR-null disease, and highlights the potential of contemporary patient-derived models to prioritise treatment strategies for clinical translation. PATIENT SUMMARY: Diverse types of therapy-resistant prostate cancers are sensitive to a new combination of drugs that inhibit protein synthesis pathways in cancer cells.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lawrence MG, Obinata D, Sandhu S, et al. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. Eur Urol. 2018. PMID: 30049486. doi:10.1016/j.eururo.2018.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。